

PROVECTUS PHARMACEUTICALS INC
Form SC 13G/A
February 12, 2013

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Provectus Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock, par value \$0.001 per share
(Title of Class of Securities)

74373F100
(CUSIP Number)

December 31, 2012
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

(Page 1 of 6 Pages)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 74373F100

13G/A

Page 2 of 6 Pages

1	NAMES OF REPORTING PERSONS	
	Revelation Special Situations Fund Ltd	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ..
		(b) ..
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Bermuda	
5	SOLE VOTING POWER	
	- 0 -	
6	SHARED VOTING POWER	
7	816,134 shares of Common Stock	
8	1,750,000 shares of Common Stock issuable upon exercise of Warrants	
9	SOLE DISPOSITIVE POWER	
	- 0 -	
10	SHARED DISPOSITIVE POWER	
	816,134 shares of Common Stock	
	1,750,000 shares of Common Stock issuable upon exercise of Warrants	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	816,134 shares of Common Stock	
	1,750,000 shares of Common Stock issuable upon exercise of Warrants	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	..
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	2.22%	
14	TYPE OF REPORTING PERSON	
	IV	

CUSIP No. 74373F100

13G/A

Page 3 of 6 Pages

1	NAMES OF REPORTING PERSONS	
	Revelation Capital Management Ltd	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ..
		(b) ..
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Bermuda	
5	SOLE VOTING POWER	
	- 0 -	
6	SHARED VOTING POWER	
7	816,134 shares of Common Stock	
8	1,750,000 shares of Common Stock issuable upon exercise of Warrants	
9	SOLE DISPOSITIVE POWER	
	- 0 -	
10	SHARED DISPOSITIVE POWER	
	816,134 shares of Common Stock	
	1,750,000 shares of Common Stock issuable upon exercise of Warrants	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	816,134 shares of Common Stock	
	1,750,000 shares of Common Stock issuable upon exercise of Warrants	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	..
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	2.22%	
14	TYPE OF REPORTING PERSON	
	IA	

CUSIP No. 74373F100

13G/A

Page 4 of 6 Pages

1	NAMES OF REPORTING PERSONS	
	Chris Kuchanny	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) <input type="checkbox"/>
		(b) <input type="checkbox"/>
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION	
	United Kingdom	
5	SOLE VOTING POWER	
	- 0 -	
6	SHARED VOTING POWER	
NUMBER OF	816,134 shares of Common Stock	
SHARES	1,750,000 shares of Common Stock issuable upon exercise of Warrants	
BENEFICIALLY		
OWNED BY	SOLE DISPOSITIVE POWER	
EACH	- 0 -	
7	SHARED DISPOSITIVE POWER	
REPORTING	816,134 shares of Common Stock	
PERSON WITH:	1,750,000 shares of Common Stock issuable upon exercise of Warrants	
8		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	816,134 shares of Common Stock	
	1,750,000 shares of Common Stock issuable upon exercise of Warrants	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES	<input type="checkbox"/>
	CERTAIN SHARES	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	2.22%	
12	TYPE OF REPORTING PERSON	
	IN	

CUSIP No. 74373F100

13G/A

Page 5 of 6 Pages

This Amendment No. 3 (this "Amendment") amends the statement on Schedule 13G filed on June 1, 2010 (the "Original Schedule 13G"), as amended by Amendment No. 1 filed on February 11, 2011 and Amendment No. 2 filed on February 14, 2012 (the Original Schedule 13G as amended, the "Schedule 13G"), with respect to shares of common stock, par value \$0.001 (the "Common Stock"), of Provectus Pharmaceuticals, Inc., a Nevada corporation (the "Company"). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Schedule 13G. This Amendment amends and restates Items 4 and 5 in their entirety as set forth below.

Item 4. OWNERSHIP.

The information required by Items 4(a) - (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

The percentage set forth in Row (11) of the cover page for each Reporting Person is based on 113,701,071 shares of Common Stock issued and outstanding as of September 30, 2012, as disclosed in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, filed with the Securities and Exchange Commission on November 8, 2012 and assumes the exercise of the warrants reported herein.

The Fund and the Fund's investment manager, Revelation, share voting and dispositive power over the shares held directly by the Fund. Mr. Kuchanny, as a principal of Revelation, shares voting and dispositive power over the shares reported by it. Each of Revelation and Mr. Kuchanny disclaims beneficial ownership of these securities (except to the extent of any pecuniary interest therein), and this report shall not be deemed an admission that either of them is the beneficial owner of such securities for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purposes.

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following[X]

CUSIP No. 74373F100

13G/A

Page 6 of 6 Pages

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: February 12, 2013

REVELATION SPECIAL SITUATIONS FUND
LTD

/s/ Chris Kuchanny
Name: Chris Kuchanny
Title: Chairman

REVELATION CAPITAL MANAGEMENT
LTD

/s/ Chris Kuchanny
Name: Chris Kuchanny
Title: Chairman and CEO

/s/ Chris Kuchanny
CHRIS KUCHANNY